About Us
Our Science
Pipeline & Programs
Partnerships
Newsroom
Contact Us
Careers
More
November 28, 2023
Aro Biotherapeutics Secures $41.5M Series B Financing
October 25, 2023
Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease
September 15, 2022
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease
August 10, 2022
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
May 11, 2022
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease
March 30, 2022
Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences
January 12, 2022
Aro Biotherapeutics Expands Leadership Team with Appointment of Sukumar Sakamuri, Ph.D. as Chief Technology Officer
October 7, 2021
Aro Biotherapeutics Appoints Mittie Doyle MD, FACR as Chief Medical Officer
August 4, 2021
Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth
February 24, 2021
Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives
January 5, 2021
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines